Journal Article

STAT3 and its targeting inhibitors in osteosarcoma

Liao, Shijie, Tang, Haijun, Wood, David, Zhan, Xinli, Song, Dezhi, Xu, Jiake, Liu, Yun, Bennett, Samuel

2021

Overview

Signal transducer and activator of transcription 3 (STAT3) is one of seven STAT family members involved with the regulation of cellular growth, differentiation and survival. STAT proteins are conserved among eukaryotes and are important for biological functions of embryogenesis, immunity, haematopoiesis and cell migration. STAT3 is widely expressed and located in the cytoplasm in an inactive form. STAT3 is rapidly and transiently activated by tyrosine phosphorylation by a range of signalling pathways, including cytokines from the IL‐6 family and growth factors, such as EGF and PDGF. STAT3 activation and subsequent dimer formation initiates nuclear translocation of STAT3 for the regulation of target gene transcription. Four STAT3 isoforms have been identified, which have distinct biological functions. STAT3 is considered a proto‐oncogene and constitutive activation of STAT3 is implicated in the development of various cancers, including multiple myeloma, leukaemia and lymphomas. In this review, we focus on recent progress on STAT3 and osteosarcoma (OS). Notably, STAT3 is overexpressed and associated with the poor prognosis of OS. Constitutive activation of STAT3 in OS appears to upregulate the expression of target oncogenes, leading to OS cell transformation, proliferation, tumour formation, invasion, metastasis, immune evasion and drug resistance. Taken together, STAT3 is a target for cancer therapy, and STAT3 inhibitors represent potential therapeutic candidates for the treatment of OS. Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT protein family, vitally important for eukaryotic cells. We review the molecular structure and function of STAT3 and its isoforms, highlighting signalling pathways for the regulation of gene transcription. A critical appraisal of STAT3 in cancers, such as osteosarcoma, is provided emphasizing potential therapeutic approaches targeting STAT3 and its inhibitors

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc
• Subject: Amino acids / Binding sites / Biomedical materials / Bone cancer / Bone Neoplasms - drug therapy / Bone Neoplasms - metabolism / Bone Neoplasms - pathology / Cancer / Cancer therapies / Cell adhesion & migration / Cell growth / Cell migration / Cytokines / Cytokines - genetics / Cytokines - metabolism / Cytoplasm / Deoxyribonucleic acid / Dimers / DNA / Drug resistance / Drug Resistance, Neoplasm / Embryogenesis / Embryonic growth stage / Enzyme Inhibitors - chemistry / Enzyme Inhibitors - therapeutic use / Epidermal growth factor / Eukaryotes / Gene regulation / Granulocytes / Growth factors / Hemopoiesis / Humans / Interleukin 6 / Isoforms / Kinases / Leukemia / Leukocytes / Lymphoma / Medical prognosis / Metastases / metastasis / Multiple myeloma / Neoplasm Metastasis / Nuclear transport / oncogenes / Osteosarcoma / osteosarcoma (OS) / Osteosarcoma - drug therapy / Osteosarcoma - metabolism / Osteosarcoma - pathology / Phosphorylation / Platelet-derived growth factor / Prognosis / Protein Isoforms - antagonists & inhibitors / Protein Isoforms - chemistry / Protein Isoforms - genetics / Protein Isoforms - metabolism / Proteins / Review / Reviews / signal transducer and activator of transcription 3 (STAT3) / Signal transduction / signalling / STAT3 inhibitor / Stat3 protein / STAT3 Transcription Factor - antagonists & inhibitors / STAT3 Transcription Factor - chemistry / STAT3 Transcription Factor - genetics / STAT3 Transcription Factor - metabolism / Transcription / Translocation / Tumors / Tyrosine